Liby, Karen T (2014) Synthetic triterpenoids can protect against toxicity without reducing the efficacy of treatment with Carboplatin and Paclitaxel in experimental lung cancer. Dose Response 12:136-51
|
To, Ciric; Kim, Eun-Hee; Royce, Darlene B et al. (2014) The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice. Cancer Prev Res (Phila) 7:698-707
|
Choi, Sung Hee; Kim, Byung-Gyu; Robinson, Janet et al. (2014) Synthetic triterpenoid induces 15-PGDH expression and suppresses inflammation-driven colon carcinogenesis. J Clin Invest 124:2472-82
|
Tran, Kim; Risingsong, Renee; Royce, Darlene B et al. (2013) The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer. Carcinogenesis 34:199-210
|
Kaidery, Navneet Ammal; Banerjee, Rebecca; Yang, Lichuan et al. (2013) Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of Parkinson's disease. Antioxid Redox Signal 18:139-57
|
Tran, Kim; Risingsong, Renee; Royce, Darlene et al. (2012) The synthetic triterpenoid CDDO-methyl ester delays estrogen receptor-negative mammary carcinogenesis in polyoma middle T mice. Cancer Prev Res (Phila) 5:726-34
|
Kim, Eun-Hee; Deng, Chuxia; Sporn, Michael B et al. (2012) CDDO-methyl ester delays breast cancer development in BRCA1-mutated mice. Cancer Prev Res (Phila) 5:89-97
|
Liby, Karen T; Sporn, Michael B (2012) Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol Rev 64:972-1003
|
Sporn, Michael B; Liby, Karen T (2012) NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer 12:564-71
|
Kim, Eun-Hee; Deng, Chu-Xia; Sporn, Michael B et al. (2011) CDDO-imidazolide induces DNA damage, G2/M arrest and apoptosis in BRCA1-mutated breast cancer cells. Cancer Prev Res (Phila) 4:425-34
|
Showing the most recent 10 out of 67 publications